In January 2014, AMW GmbH was able to conclude a semi-exclusive license and supply contract for its biodegradable goserelin implants with a multinational pharmaceutical company.
The contract applies to Southeast Asia, including China, Eastern Europe, Russia and some Western European countries. The agreements contain down payment payments of up to € 10 million, license payments in the double-digit percentage range, and an exclusive delivery agreement for AMW. The partner company will carry out further clinical developments for the contract area.
The contract applies to Southeast Asia, including China, Eastern Europe, Russia and some Western European countries.
The agreements contain down payment payments of up to € 10 million, license payments in the double-digit percentage range, and an exclusive delivery agreement for AMW. The partner company will carry out further clinical developments for the contract area.
AMW GmbH independently developed the product with the 3.6 and 10.8 mg doses. It is clinically equivalent to the Zoladex® depot originator.
In addition, it offers the doctor and patient convincing handling and application advantages thanks to its innovative implant applicator.